NEW YORK, Sept. 8, 2016 /PRNewswire/ -- Rosen Law
Firm, a global investor rights law firm, reminds purchasers of
Keryx Biopharmaceuticals, Inc. securities (NASDAQ: KERX) from
February 25, 2016 through
August 1, 2016, both dates inclusive
(the "Class Period") of the important October 3, 2016 lead plaintiff deadline in the
class action. The lawsuit seeks to recover damages for Keryx
Biopharmaceuticals investors under the federal securities laws.
To join the Keryx Biopharmaceuticals class action, go to the
firm's website at http://rosenlegal.com/cases-927.html or call
Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or
email pkim@rosenlegal.com or kchan@rosenlegal.com for more
information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A
CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO
NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants
issued false and misleading statements to investors and/or failed
to disclose that: (1) Keryx Biopharmaceuticals was experiencing
production-related difficulties in converting API to finished drug
product; (2) the issue was resulting in decreased production yields
of finished drug product; and (3) as a result, defendants'
statements about Keryx Biopharmaceuticals' business and operations
were false and misleading and/or lacked a reasonable basis. When
the true details entered the market, the lawsuit claims that
investors suffered damages.
A class action lawsuit has already been filed. If you wish to
serve as lead plaintiff, you must move the Court no later than
October 3, 2016. A lead plaintiff is
a representative party acting on behalf of other class members in
directing the litigation. If you wish to join the litigation, go to
the firm's website at http://rosenlegal.com/cases-927.html for more
information. You may also contact Phillip
Kim, Esq. or Kevin Chan, Esq.
of Rosen Law Firm toll free at 866-767-3653 or via email at
pkim@rosenlegal.com or kchan@rosenlegal.com. Attorney
Advertising. Prior results do not guarantee a similar
outcome.
Follow us for updates on LinkedIn:
https://www.linkedin.com/company/the-rosen-law-firm or on Twitter:
https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
Logo - http://photos.prnewswire.com/prnh/20160907/405060LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/investor-alert-rosen-law-firm-reminds-keryx-biopharmaceuticals-inc-investors-of-important-october-3-deadline-in-class-action---kerx-300324999.html
SOURCE Rosen Law Firm, P.A.